StoryFunding
Colossal Biosciences secures $200M Series C funding at $10.2B valuation led by TWG Global
Colossal Biosciences raised $200M in Series C funding from TWG Global, bringing the company's valuation to $10.2B and total raised to $435M. The funding will accelerate de-extinction projects across woolly mammoth, thylacine, dodo, and moa, with CEO Ben Lamm reaffirming the goal to produce a woolly mammoth calf by late 2028.